ArticleCancer immunology, immunotherapy : CII2023

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.

Joshua F Meckler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.